FarmaKeio Superior Custom Compounding (North American Custom Laboratories, LLC), Richardson, TX
Is FarmaKeio Superior Custom Compounding (North American Custom Laboratories, LLC) registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does FarmaKeio Superior Custom Compounding (North American Custom Laboratories, LLC) hold a Texas pharmacy license?
No license with this exact name and city was found in the Texas State Board of Pharmacy file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054019497 for NORTH AMERICAN CUSTOM LABORATORIES LLC, RICHARDSON, TX, status ACTIVE, as of Nov 13, 2026. The Delaware Division of Professional Regulation also lists nonresident license A9-0012591 for North American Custom Laboratories, RICHARDSON, TX, status Closed, as of Nov 10, 2026. The Michigan Department of Licensing and Regulatory Affairs also lists nonresident license 5301012396 for North American Custom Laboratories, LLC, Richardson, TX, status Active, as of Nov 10, 2026.
Has FarmaKeio Superior Custom Compounding (North American Custom Laboratories, LLC) had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Nov 18, 2022), 1 warning letter close-out (Jan 27, 2026) and 1 FMD-145 letter (Jan 30, 2026) for FarmaKeio Superior Custom Compounding (North American Custom Laboratories, LLC). Texas board disciplinary orders: not checked, because the board’s file flags orders only on a license, and no license matched this name and city.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- North American Custom Laboratories, LLC; FarmaKeio Superior Custom Compounding
- Location
- Richardson, TX
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 2
- Warning letters on FDA’s actions page
- 1
- Latest action on that page
- Jan 30, 2026
- FDA Data Dashboard inspections
- 2 inspections: 1 OAI, 1 VAI; 2 published Form 483s
- Form 483 text on this page
- 2 Form 483s, 9 observations
- State board records
- No exact match
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as North American Custom Laboratories, LLC (dba FarmaKeio Superior Custom Compounding), a 503A facility, with 6 dated actions.
| Document | |||
|---|---|---|---|
| Jan 30, 2026 | FMD-145 letter | FMD-145 Letter Issued 01/30/2026 | Not linked by FDA |
| Jan 27, 2026 | Warning letter close-out | Warning Letter Close Out Issued 01/27/2026 | fda.gov |
| Sep 5, 2025 | Form 483 | 483 Issued 09/05/2025 | fda.gov |
| Nov 18, 2022 | Warning letter | Warning Letter Issued 11/18/2022 | FDA copy (archived) |
| Mar 30, 2022 | Press release or statement | FDA Statement: FDA warns patients and health care professionals not to use sterile products from North American Custom Laboratories LLC, dba FarmaKeio Superior Custom Compounding (3/30/2022) | FDA copy (archived) |
| Mar 10, 2022 | Form 483 | 483 Issued 03/10/2022 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists North American Custom Laboratories, LLC, Richardson, TX (FEI number 3014229024), matched to this page by exact name, city and state. It lists 2 inspections: 1 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Sep 5, 2025 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3014229024 | 1280796 |
| Mar 10, 2022 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3014229024 | 1164181 |
Form 483s FDA has published for this site
- Sep 5, 2025: Form 483 to North American Custom Laboratories, LLC, published Nov 26, 2025. fda.gov
- Mar 10, 2022: Form 483 to North American Custom Laboratories, LLC, published Sep 27, 2022. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 9 numbered observations in all, across 2 inspections ending Mar 10, 2022 to Sep 5, 2025. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Aug 25, 2025 to Sep 5, 2025: 1 observation
- Firm on the cover
- North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding, 1736 N Greenville Ave, Richardson, TX 75081-1808
- FEI number
- 3014229024
- Establishment type on the cover
- Producer of Sterile and Non-sterile Drug Products
- FDA district office on the cover
- 1201 Main Street, Suite 7200 Dallas, TX 75202
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Production areas have difficult to clean or contain porous, particle generating, or visibly duty equipment or surfaces.
Specifically,
On 08/25/2025, I observed the following inside your firm's ISO 7 classified buffer room around the ISO 5 laminar flow hood (LFH) used for non-hazardous sterile compounding:
A) Chipped paint around the HEPA filter directly above the ISO 5 LFH (Asset #022: <Redacted B4>.
B) Peeling/hanging paint on the ceiling tile above the ISO 5 LFH (Asset #0222, SIN <Redacted B4>), and
b) (4) C) A gap in the paneling behind the ISO 5 LFH (Asset #0222, S/N <Redacted B4> ).
4)
t.
Accordin g to th e PIC, these defects could have been present for at least the last <Redacted B4> since the previous <Redacted B4> cleaning performed on 07/24/2025. Between 07/25/2025
an d 08/25/2025, app roximately <Redacted B4> lots of sterile compounded drug products were prep ared in this compromised environment, including Pyridoxine Hydrochloride/Tirzepatide (25mg/18mg)/m L (2mL) injection, lot LG7642921, beyond use date (BUD) 11/16/2025, compounded on 08/18 /2025 and dispensed on 08/25/2025 to a patient in Houma, Louisiana. ...
Inspection Mar 1, 2022 to Mar 10, 2022: 8 observations
- Firm on the cover
- North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding, 1736 N Greenville Ave, Richardson, TX 75081-1808
- FEI number
- 3014229024
- Establishment type on the cover
- Producer of Sterile and Non-Sterile Drug Products
- FDA district office on the cover
- 1201 Main Street, Suite 7200 Dallas, TX 75202
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
The <Redacted B4> intended to render final product sterile was not pharmaceutical grade.
Specifica lly,
On 3/1/2022 I observed the Pharmacist in Charge use <Redacted B4> <Redacted B4, non-pharmaceutical grade sterile <Redacted B4> to <Redacted B4> sterilize a solution of Sermorelin Acetate lmg/ml, Lot #34585 with a beyond use date of 05/30/2022. In addition, the <Redacted B4> test conducted on the non-pharmaceutical grade <Redacted B4> post compounding was inadequate because no <Redacted B4> was used while performing the test.
On 2/18/2022, a non-pharmaceutical grade <Redacted B4> was used to <Redacted B4> a solution of OC-1295 Acetate/ pamorelin Acetate Injection Lot #34383 with a beyond use date of 08/ 17/ 2022. An inadequate <Redacted B4> <Redacted B4> test was conducted on that <Redacted B4> also and the drug product were distributed to patients nationwide.
Observation 2
Materials or supplies were not disinfected prior to entering the aseptic processing areas.
Specifica lly,
On 3/1/2021, a plastic tote containing materials and supplies such as but not limited to sterile tubing, sterile <Redacted B4> sterile vials and sterile rubber stoppers used in the aseptic compounding of Sermorelin Acetate, Lot #34824, BUD 05/30/ 2022 wwas not disinfected when placed in the <Redacted B4> located in the ISO 8 non-sterile compounding room nor were they disinfected when introduced into the ISO 5 buffer room or the ISO 5 LAFH where aseptic operations are conducted.
Observation 3
Non-sterilized equipment was used in sterile drug production.
Specifically,
a) On 3/1/2022. I observed your Pharmacist in Charge remove non-sterile scissors and a non-sterile hand held <Redacted B4> from a drawer located in the ISO 5 buffer room, wipe the non-sterile equipment with sterile <Redacted B4> placed them in the ISO 5 LAFH and use them in the <Redacted B4> process of Sermorelin Acetate Injection Lot #34585, BUD 05/ 30/ 2022.
b) On 3/1/2022, upon completion of aseptic activities of Sermorelin Acetate 1mg/ ml, Lot #34585 with a BUD of 05/30/2022, I observed your Pharmacist in Charge (PIC) clean/ disinfect the ISO 5 buffer room floor using of <Redacted B4> a non sterile disinfectant. According to your PIC, the floors of the ISO 5 buffer room are disinfected using <Redacted B4> and <Redacted B4> a non-sterile quaternary based disinfectant on a <Redacted B4> basis.
Observation 4
You did not make adequate product evaluation and take remedial action where actionable microbial contamination was found to be present in an area adjacent to the ISO 5 classified aseptic processing area during aseptic production.
Specifically,
Your firm conducts environmental sampling (air and surface) of your ISO classified areas every <Redacted B4>. During the most recent environmental sampling conducted on 10/26/2021, there were actionable microbial contamination in your designated ISO 5 areas. Microbial isolates were not sent out for speciation to determine appropriate remedial actions and no assessment was conducted to evaluate whether or not sterile drugs product produced during that timeframe were negatively impacted.
Observation 5
You produced highly potent drugs without providing adequate containment to prevent crosscontamination.
Specifically,
On 3/1/2022, I observed your technician prepare a batch of <Redacted B4> vegetarian capsules containing Progesterone 200mg, Lot #34585, BUD 08/21/2022 in your negative pressure hazardous room dedicated to the production of non-sterile drug products containing potent and/ or potentially hazardous bulk drug substances such as hormones.
There was visible pink residue located on the ceiling wall directly where the vents to of the <Redacted B4> containment hoods are located, visible pink residue on the exhaust vent and visible pink residue on the broom kept in the dedicated hazardous room. According to the National Director of Business Solutions, <Redacted B4>. In addition, finished product capsules of Progesterone 200mg, Lot #34585 were observed in plastic container on a stainless table exposed to the environment.
Your firm's current controls to contain potent and potentially hazardous non-sterile drug products to prevent cross contamination is insufficient. ...
Observation 6
You used a non-pharmaceutical grade component in the formulation of a drug product.
Specifica lly,
1. Your firm routinely uses non-pharmaceutical grade components for compounding drug products. A review of the Certificate of Analysis for various components noted that the following non-pharmaceutical grade components were used in processing injectable drug products:
• C-1295 Acetate <Redacted B4>, Lot <Redacted B4> Exp: 06/02/24 was used in CJC-1295 Acetate/lpamorelin Acetate <Redacted B4> mg <Redacted B4> mg/ml ml) lnjection, Lot #34383, BUD: 08/17/2022.
BPC-157 Acetate <Redacted B4>, Lot <Redacted B4> Exp: 02/23/2023 was used in BPC-157 Acetate g/ml Injection, Lot #27757, BUD: 12/01/2021
• Sermor elin Acetate <Redacted B4> Lot <Redacted B4> Exp: 11/20/2021 was used in Sermorelin Acetate <Redacted B4> mg/ml <Redacted B4> Injection, Lot #32963, BUD: 04/12/2022.
2. Your firm uses a commercially available household detergents, <Redacted B4> Detergent and <Redacted B4> to clean/sanitize reusable equipment such glass beakers that are routinely used in the production of your compounded sterile injectable drug products. ...
Observation 7
Smoke studies performed under dynamic conditions are inadequate.
Specifically,
Your firm's dynamic smoke studies only demonstrated your sterile technician ability to set sterile tubing in the <Redacted B4>. You failed to conduct smoke studies on the most critical aspect of your aseptic process which is the <Redacted B4> of the solution, aseptic filling of your vials and aseptic placement of rubber stoppers to ensure that your sterile technician does not alter, impede or block t he unidirectional flow of <Redacted B4> during aseptic processing.
Observation 8
Failure to conduct media fills that closely simulates aseptic compounding operations under the worst case, most challenging and stressful conditions.
Specifically,
Your Pharmacist in Charge (PIC) media fill conducted on 3/11/2021 consists of a total of <Redacted B4> test vials which does not represent routine compounding, worse case scenarios, most challenging and/ or stressful conditions. For example, your PIC routinely compounds the following sterile drug product quantities.
• Approximatel <Redacted B4> vials of CJC-1295 Acetate/ lpamorelin Acetate! <Redacted B4> mg/ml <Redacted B4> ml injection Lot #34383, BUD 08/ 17/ 2022 was produced on 2/18/2022.
• Approximately <Redacted B4> vals of Sermorelin Acetate <Redacted B4> mg/ ml <Redacted B4> Injection, Lot #32963, BUD 04/12/2022 was produced on 1/12/ 2022.
State board of pharmacy records
No license with this exact name and city was found in the Texas State Board of Pharmacy file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. Board file.
What this covers: The file marks whether a license has prior disciplinary orders (column DISP ACTN, Y or N) but does not list them; the orders are on the board’s license lookup, which this index does not copy. The board says orders entered more than 10 years ago are not online.
Nonresident licenses in other states
These boards list a nonresident license whose record names this pharmacy’s own name, city and state.
Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 054019497 | LICENSED PHARMACY | NORTH AMERICAN CUSTOM LABORATORIES LLC | RICHARDSON, TX | ACTIVE |
Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| A9-0012591 | Non Resident Pharmacy | North American Custom Laboratories | RICHARDSON, TX | Closed |
Michigan Department of Licensing and Regulatory Affairs, file dated Nov 10, 2026 (Michigan).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 5301012396 | Pharmacy | North American Custom Laboratories, LLC | Richardson, TX | Active |
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- Texas State Board of Pharmacy license file
- Illinois Department of Financial and Professional Regulation license file
- Delaware Division of Professional Regulation license file
- Michigan Department of Licensing and Regulatory Affairs license file
- Texas State Board of Pharmacy disciplinary records
- Delaware Division of Professional Regulation disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.